XOMA Makes Cost-Cutting Move by Restructuring Novartis Deal
By Helen Scrutton
Pharma Deals Review: Vol 2008 Issue 102 (Table of Contents)
Published: 10 Nov-2008
DOI: 10.3833/pdr.v2008.i102.108 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
XOMA is the latest in a long line of companies forced to relinquish development programmes in order to save money...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS